PRISYS Biotech is pleased to share the achievements and advancements made in 2024 through our one-of-a-kind Non-Human Primate (NHP) Translational R&D Center. Over the past year, we have successfully supported over 50 global collaborators by providing high-quality preclinical research services, including drug efficacy evaluation, safety assessment, drug metabolism and pharmacokinetics (DMPK), biodistribution studies, and IND submissions.
Figure1: PRISYS Supports Global Drug Development with NHP Models and Technology
Our innovative NHP models and technologies have enabled significant progress in various therapeutic areas, reinforcing our commitment to accelerating drug development and translational research.
2024 Research Highlights
In 2024, PRISYS Biotech demonstrated the reliability and versatility of our NHP models across multiple therapeutic areas:
- Ischemic Stroke
- Parkinson's Disease
- Rheumatoid Arthritis (RA)
- Atopic Dermatitis (AD)
- Asthma
- Inflammation
- Anemia
- Bleeding Disorders
- Coagulation Disorders
- Thrombosis
Metabolism
- Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)
- Obesity
- Type 2 Diabetes
Ophthalmology
- Glaucoma
- Retinitis Pigmentosa and Neovascularization
Innovative Technologies
Real-Time MRI Navigation (RT-iMRI): Facilitating precision drug delivery through convection-enhanced delivery (CED) in the brain.
AI-Based NHP Behavior Analysis System: Providing automated classification and quantification of behavioral data for disease manifestation, drug efficacy, and safety evaluation.
Figure 2: Model of Atopic March (linking Atopic Dermatitis and Asthma) and AI-based 3D quantification of pruritus in AD.
Figure 3: BOLD fMRI detection of pain signals induced by capsaicin irritation.
2025 Pipeline: Expanding NHP Models and Technologies
As we look ahead to 2025, PRISYS Biotech is committed to further expanding our capabilities with the introduction of novel NHP models and advanced technologies. These new offerings are designed to address emerging challenges and accelerate drug development in key therapeutic areas:
Neuroscience
- Alzheimer's Disease
- Comprehensive Pain Assessment
Immunology
- Intestinal MRI Scoring for Inflammatory Bowel Disease (IBD)
- DermaLab Skin Analysis for Psoriasis
- Accelerated Multiple Sclerosis (MS) Development
Metabolism
- Progressive and Chronic Heart Failure
- Renal Failure
- Liver Failure
- BSL-2 Pathogen Exposure
- Idiopathic Pulmonary Fibrosis (IPF)
- Chronic Obstructive Pulmonary Disease (COPD)
Innovative Technology
Nasal-to-Brain (N2B) Drug Delivery Solutions
Our innovative N2B platform is designed to enhance drug delivery efficiency to the central nervous system, offering a promising route for treating neurological and neurodegenerative diseases.
Driving Innovation in Preclinical Research
At PRISYS Biotech, we are dedicated to providing our global partners with reliable, high-quality NHP models and cutting-edge technologies to support preclinical research and drug development. Our continued efforts to expand our offerings and improve model reliability aim to address the evolving needs of the pharmaceutical and biotechnology industries.
We invite our partners and collaborators to explore the possibilities of working with PRISYS Biotech in 2025 and beyond. Together, we can drive innovation and bring transformative therapies to patients worldwide.
For more information, please contact us or visit our website www.prisysbiotech.com.
